Você procurou por: splenomegaly (Inglês - Esloveno)

splenomegaly
plenomegalija

splenomegaly a
plenomegalijaa

splenomegaly anaemia
splenomegalija anemija

anaemia, splenomegaly
anemija, splenomegalija

leukocytosis*, splenomegaly*
levkocitoza*, splenomegalija

hepatomegaly or splenomegaly
hepatomegalija ali splenomegalija.

spleen disorder, splenomegaly*
motnje v delovanju vranice, splenomegalija *

splenomegaly and splenic rupture
splenomegalija in ruptura vranice

thrombocythaemia splenomegaly lymphadenopathy hypochromasia
trombocitemija splenomegalija limfadenopatija hipokromazija

enlargement of the spleen (splenomegaly)
povečanje vranice (splenomegalija)

splenomegaly, generally asymptomatic, is uncommon.
občasen neželen učinek je splenomegalija, praviloma asimptomatska.

splenomegaly and splenic rupture were also reported.
poročali so tudi o splenomegaliji in raztrganju vranice.

in hiv patients enlargement of the spleen (splenomegaly)
pri bolnikih s hiv povečanje vranice (splenomegalija)

splenomegaly is a direct effect of treatment with filgrastim.
neposredna posledica zdravljenja s filgrastimom je splenomegalija.

pancytopaenia, splenomegaly, erythrocytosis, white blood cell morphology abnormal
pancitopenija, splenomegalija, eritrocitoza, morfološke nepravilnosti belih krvnih celi

this may be a sign of a problem with your spleen (splenomegaly)
to je lahko znak, da imate težave z vranico (splenomegalija).

cases of splenomegaly have been reported commonly following administration of filgrastim.
po dajanju filgrastima so pogosto poročali o primerih splenomegalije.

31% of patients in studies were documented as having palpable splenomegaly.
v študijah je 31% bolnikov imelo tipljivo splenomegalijo.

in the spleen, lal deficiency results in splenomegaly, anemia, and thrombocytopenia.
v vranici povzroči pomanjkanje lal splenomegalijo, anemijo in trombocitopenijo.

splenomegaly, generally asymptomatic, has been reported (see section 4.4).
poročali so o običajno asimptomatski splenomegaliji (glejte poglavje 4.4).